07 Jan 2001

Vigantoletten® 500 (Vigantoletten® 500/-1000 Tabletten) - Deutschland

Updated: 07 Jan 2001

Vigantoletten® 500 | -1000

Vorbeugung gegen Rachitis beim Sgl. Vorbeugung bei erkennbarem Risiko einer Vit.-D-Mangelerkrankung, Vorbeugung von Vit.-D-Mangelerscheinungen bei Verdauungsschwäche, z. B. durch chronische Darmerkrankungen, narbigen Umbau des Lebergewebes, Entfernung großer Teile des Magens oder Darms, Behandl. von Rachitis und Knochenerweichung durch Vit.-D-Mangel, unterstützende Behandl. bei Osteoporose.

Vigantoletten® 500 Description, Presentation and Dosage

Vigantoletten® 500 Description

Vigantoletten® 500 Drug Class Description

Andere Einzelstoffe

Vigantoletten® 500 Drug Description

1 Tbl. enth.: Colecalciferol 0,0125 mg/0,025 mg (entspr. 500 I.E./1000 I.E. Vit. D3).

Vigantoletten® 500 Generic Name

Vigantoletten® 500/-1000 Tabletten

Vigantoletten® 500 Presentation

Vigantoletten® 500 Presentation

Vigantoletten® 500/-1000

Vigantoletten® 500 Manufacturer

Merck

Related Learning Zones

CLL Knowledge Centre and CME

CLL Knowledge Centre and CME

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within four main sections: ‘Disease Awareness’, ‘Events’, ‘Resources’, and 'CME'. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing,

The CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been EACCME-accredited and awarded 1 CME credit. Test your knowledge by answering quiz questions based on patient case study scenarios.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Vigantoletten® 500 Dosage

Vigantoletten® 500 Adult Dosage

Siliciumdioxid, Maisstärke, Carboxymethylstärke-Natrium, Talkum, Glyceroltristearat, Cellulose, D-Mannitol, Gelatine, Saccharose, teilhydrierte Pflanzenöle (Sojaöl), 'alpha'-Tocopherol.

Vigantoletten® 500 Precautions, Reactions and Contraindications

Vigantoletten® 500 Special Precautions

Vigantoletten® 500 Special Precautions

V 15

Vigantoletten® 500 Adverse Reactions

Vigantoletten® 500 Adverse Reactions

V 15

Related Drugs - Rheumatology

Back to top